Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.
Johnson & Johnson is riding the tailwinds of recent success, celebrating positive third quarter earnings buoyed by record-setting sales of its top products and the sell-off of its Ortho-Clinical Diagnostics business.
Last week, Sanofi told the feds it had hired an outside law firm to dive into an anonymous whistleblower's accusations of corruption in the Middle East. But the company's proactive approach may not be enough to block a blow to its reputation, experts say.
AstraZeneca has launched a photo-sharing campaign on Twitter, Instagram and other social media sites to get women talking about their metastatic breast cancer (MBC).
Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmacueticals is preparing to take over, the company's top U.S. leadership is throwing in the towel.
Pfizer's pipeline could use a big approval, and it may have one coming in palbociclib.
Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.
So you thought Gilead's Sovaldi was expensive? Get ready for Harvoni, the company's all-oral hep C combo regimen that won FDA approval on Friday. Cost? $94,500 for a 12-week course of treatment.
India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.
Months after launching a regulatory battle to extend exclusivity for two of its best-selling products, Eisai won FDA approval for its Akynzeo drug to treat common side effects in patients undergoing chemotherapy.
When it comes to interactions between doctors and pharmaceutical companies, there's a growing desire for transparency among those concerned that reps influence prescribing habits. But an Australian group of doctors and academics wants to take it one step further: With an aptly titled "No Advertising Please" campaign, it's pushing to end doc-rep interactions altogether.
As Sweden's Meda wraps up its buyout of the Italian drugmaker Rottapharm, it's rolling out a rights issue--to the tune of 2 billion kronor, or about $276 million--to help finance the deal.
Turning the ancient gout remedy colchicine into an FDA-approved drug may not have been as costly an endeavor as developing a new med from scratch. But Takeda Pharmaceuticals still wants to reap brand-level sales for its version, dubbed Colcrys--and it's suing the FDA to make sure that happens.
Tuesday, two women pleaded guilty in a Polish court to handing a health fund official a trip worth more than $1,000 in exchange for backing the sale of a certain drug. And one of those women was a Novartis employee, the company said Thursday.
Did Bristol-Myers Squibb offer kickbacks and push Abilify for off-label uses? Some former sales reps-turned-whistleblowers claim it did. And given the fact that Bristol-Myers already paid $515 million to settle some off-label marketing claims related to Abilify, they say, the company violated its "we'll behave" promises to the feds.
Last October, the Pharmaceutical Research and Manufacturers of America (PhRMA) sued the federal government over a rule that allowed some hospitals to get orphan drugs at a steep discount. At first, it looked like the trade group had prevailed, because in May, a federal court struck down the authority of the U.S. Health Resources and Services Administration (HRSA) to enforce the rule.
Back in August, Impax Laboratories CEO Fred Wilkinson told investors on a conference call that the company was "well-positioned to execute on a number of transactions." And now, the company has pulled the trigger on one of those deals, spending $700 million on a pair of Pennsylvania drugmakers.
It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.
As Big Pharma's big patent cliff took hold a few years ago, generics makers enjoyed the sales boost of one newly off-patent blockbuster after another. But savvy execs knew that the unprecedented party would end soon enough--and generics companies would be facing a sort of patent cliff of their own.